2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2128 Acalabrutinib versus ibrutinib in chronic lymphocytic leukemia with pre-existing atrial fibrillation: A propensity score-matched analysis of survival and bleeding outcomes

Maida Sarfraz Chaudhry, MD, Ammar Al Heyasat, MD2, Mohammad Bani Amer, MD3
1 University of Minnesota, Minneapolis, Minnesota, United States
2 Cleveland Clinic, Weston, Florida, United States
3 Crestwood Medical Center, Huntsville, Alabama, United States

Introduction 

Bruton tyrosine kinase inhibitors (BTKi) are standard therapy in chronic lymphocytic leukemia (CLL), but ibrutinib carries well-described cardiovascular and bleeding toxicity. Acalabrutinib demonstrated fewer cardiac events than ibrutinib in ELEVATE-RR; however, that trial excluded patients requiring anticoagulation, leaving comparative safety unresolved in the population where the choice between agents is most consequential: patients with pre-existing atrial fibrillation (AF). We compared bleeding, cardiovascular, and mortality outcomes between acalabrutinib and ibrutinib in CLL patients with AF documented prior to treatment initiation. 

Methods 

We conducted a retrospective cohort study using the TriNetX US Collaborative Network, a federated EHR database of approximately 128 million patients across 70 healthcare organizations. Adults with CLL (ICD-10-CM C91.1) and atrial fibrillation or flutter (I48) documented prior to index were identified. Cohort 1 initiated acalabrutinib; Cohort 2 initiated ibrutinib. Patients with any exposure to the comparator BTKi, zanubrutinib, or pirtobrutinib were excluded, as were patients with mantle cell lymphoma, Waldenstrom macroglobulinemia, extranodal marginal zone lymphoma, follicular lymphoma, or graft-versus-host disease. The index event was first administration of the cohort-defining BTKi. Cohorts underwent 1:1 propensity score matching (greedy nearest neighbor, caliper 0.1 SD) on age, sex, race, ethnicity, hypertension, heart failure, ischemic heart disease, type 2 diabetes, chronic kidney disease, cerebral infarction, transient ischemic attack, tobacco use, obesity, long-term antithrombotic use, anticoagulants, rituximab, obinutuzumab, venetoclax, and lactate dehydrogenase. Outcomes were assessed 1 to 1,095 days after index, excluding patients with the outcome prior to the window. Risk ratios (RR) and Kaplan-Meier hazard ratios (HR) with 95% confidence intervals were calculated. 

Results 

Prior to matching, 773 acalabrutinib and 1,709 ibrutinib patients met criteria. After 1:1 propensity score matching, 624 patients remained per cohort, with all standardized mean differences below 0.1. All-cause mortality was significantly lower with acalabrutinib (26.3% vs 32.6%; RR 0.81, 95% CI 0.68-0.96, p=0.015), a difference confirmed in time-to-event analysis (HR 0.79, 95% CI 0.64-0.97; log-rank p=0.021), with 3-year survival probability 68.0% versus 62.3%. No bleeding endpoint differed significantly between cohorts. Gastrointestinal hemorrhage occurred in 3.9% versus 4.9% (RR 0.80, 95% CI 0.47-1.37; HR 0.78, log-rank p=0.38), melena in 4.4% versus 4.0% (RR 1.09, 95% CI 0.64-1.88; HR 1.07, p=0.82), acute posthemorrhagic anemia in 7.3% versus 8.5% (RR 0.86, 95% CI 0.58-1.28; HR 0.84, p=0.41), and other nontraumatic intracranial hemorrhage in 2.2% versus 3.5% (RR 0.64, 95% CI 0.33-1.23; HR 0.74, p=0.42). Subarachnoid and intracerebral hemorrhage counts fell below the reporting threshold. Cardiac endpoints also did not differ: ventricular tachycardia 4.6% versus 5.5% (RR 0.83, 95% CI 0.50-1.37; HR 0.81, p=0.42) and heart failure 21.2% versus 23.0% (RR 0.92, 95% CI 0.72-1.18; HR 0.91, p=0.53). 

Conclusions 

In this real-world cohort of CLL patients with pre-existing atrial fibrillation, a population underrepresented in randomized comparison, acalabrutinib was associated with significantly lower all-cause mortality than ibrutinib, consistent across both risk-ratio and time-to-event analyses. Notably, this survival advantage occurred without any measurable difference in bleeding, including gastrointestinal and intracranial hemorrhage, despite the anticoagulant burden expected in this population. Rates of ventricular arrhythmia and heart failure were also comparable. These findings suggest that the survival benefit is not mediated by reduced hemorrhagic events and may instead reflect differences in treatment persistence, non-hemorrhagic toxicity, or residual confounding by unmeasured disease severity, although a prespecified negative control outcome argued against gross residual confounding. Limitations include retrospective design, reliance on diagnostic coding, incomplete overlap of propensity distributions before matching, potential differential follow-up given the later approval of acalabrutinib, and unmeasured confounding by indication. These results support acalabrutinib as a reasonable choice in CLL patients with pre-existing AF and warrant prospective evaluation. 

Maida Sarfraz Chaudhry, MD: No relevant conflicts of interest to declare.